2 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Not approvedWill not start
Primary objectiveThe primary objective of this study is to evaluate the efficacy of bimekizumab in subjects with moderate to severe HS.Secondary objectiveThe secondary objective of this study is to assess the safety, tolerability, immunogenicity,…